Rockbridge Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rockbridge Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-60	Closed	-$4.97K	–	166
2022 Q2	$4.97K	Hold	60	–	–	﹤0.01%	463
2022 Q1	$4.76K	Sell	60 -1,055	-95%	-$88.3K	﹤0.01%	628
2021 Q4	$99K	Hold	1,115	–	–	0.01%	257
2021 Q3	$86K	Hold	1,115	–	–	0.01%	253
2021 Q2	$93K	Hold	1,115	–	–	0.02%	233
2021 Q1	$84K	Buy	1,115 +60	+6%	+$4.9K	0.02%	233
2020 Q4	$93K	Hold	1,055	–	–	0.02%	211
2020 Q3	$80K	Buy	+1,055	New	+$107K	0.02%	209

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Rockbridge Investment Management's BMRN Position: Q3 2022 in Review

Rockbridge Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 60 shares — an estimated $4.97K sold.

Rockbridge Investment Management first reported a position in BMRN in Q3 2020 and held it in 8 quarters. The position peaked at $99K in Q4 2021. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Rockbridge Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Rockbridge Investment Management sold 60 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $4.97K.
Rockbridge Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 8 quarters.
Rockbridge Investment Management's BioMarin Pharmaceuticals position peaked at $99K in Q4 2021.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Rockbridge Investment Management's 13F filing for Q3 2022, filed 28 May 2024.